Chromogranin a and the endothelial barrier function

Current Medicinal Chemistry

Volumn 19, Issue 24, 2012, Pages 4051-4058

  Corti, A ^a   Ferrero, E ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Angiogenesis; Cancer; Chromogranin A; Endothelial barrier function; Endothelial cell; Neuroendocrine tumors; NGR TNF; TNF; Vascular leakage; Vasostatin 1; VE cadherin; VEGF

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CATESTATIN; CHROMOGRANIN A; CYTOKINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG; VASOSTATIN 1;

ANGIOGENESIS; ARTICLE; BREAST CANCER; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; LUNG NON SMALL CELL CANCER; NEOPLASM; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SECRETORY GRANULE;

CADHERINS; CHROMOGRANIN A; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; NEOVASCULARIZATION, PATHOLOGIC; NEUROENDOCRINE TUMORS; PEPTIDE FRAGMENTS; TUMOR NECROSIS FACTORS;

EID: 84866683880     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712802429975     Document Type: Article

References (133)

1. Helle, K.B.; Corti, A.; Metz-Boutigue, M.H.; Tota, B., The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell. Mol. Life Sci., 2007, 64, 2863-2886.
2. Portela-Gomes, G.M.; Grimelius, L.; Wilander, E.; Stridsberg, M., Granins and granin-related peptides in neuroendocrine tumours. Regul. Pept., 2010, 165(1), 12-20.
3. Taupenot, L.; Harper, K.L.; O'Connor, D.T., The chromograninsecretogranin family. N. Engl. J. Med., 2003, 348(12), 1134-1149.
4. Deftos, L.J., Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr. Rev., 1991, 12(2), 181-187.
5. Janson, E.T.; Holmberg, L.; Stridsberg, M.; Eriksson, B.; Theodorsson, E.; Wilander, E.; Oberg, K., Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann. Oncol., 1997, 8(7), 685-690.
6. Lugardon, K.; Raffner, R.; Goumon, Y.; Corti, A.; Delmas, A.; Bulet, P.; Aunis, D.; Metz-Boutigue, M.H., Antibacterial and antifungal activities of vasostatin-1, the N-terminal fragment of chromogranin A. J. Biol. Chem., 2000, 275, 10745-10753.
7. Pieroni, M.; Corti, A.; Tota, B.; Curnis, F.; Angelone, T.; Colombo, B.; Cerra, M.C.; Bellocci, F.; Crea, F.; Maseri, A., Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur. Heart J., 2007, 28(9),1117-27.
8. Steiner, H.J.; Weiler, R.; Ludescher, C.; Schmid, K.W.; Winkler, H., Chromogranins A and B are co-localized with atrial natriuretic peptides in secretory granules of rat heart. J. Histochem. Cytochem., 1990, 38(6), 845-850.
9. Biswas, N.; Curello, E.; O'Connor, D.T.; Mahata, S.K., Chromogranin/secretogranin proteins in murine heart: myocardial production of chromogranin A fragment catestatin (Chga(364-384)). Cell Tissue Res., 2010, 342(3), 353-361.
10. Glattard, E.; Angelone, T.; Strub, J.M.; Corti, A.; Aunis, D.; Tota, B.; Metz-Boutigue, M.H.; Goumon, Y., Characterization of natural vasostatincontaining peptides in rat heart. Febs J, 2006, 273(14), 3311-3321.
11. Radek, K.A.; Lopez-Garcia, B.; Hupe, M.; Niesman, I.R.; Elias, P.M.; Taupenot, L.; Mahata, S.K.; O'Connor, D.T.; Gallo, R.L., The neuroendocrine peptide catestatin is a cutaneous antimicrobial and induced in the skin after injury. J. Invest. Dermatol., 2008, 128(6), 1525-1534.
12. Stridsberg, M.; Eriksson, B.; Oberg, K.; Janson, E.T., A panel of 11 regionspecific radioimmunoassays for measurements of human chromogranin A. Regul. Pept., 2004, 117(3), 219-227.
13. Portel-Gomes, G.M.; Grimelius, L.; Johansson, H.; Wilander, E.; Stridsberg, M., Chromogranin A in human neuroendocrine tumors: an immunohistochemical study with region-specific antibodies. Am. J. Surg. Pathol., 2001, 25(10), 1261-1267.
14. O'Connor, D.T.; Bernstein, K.N., Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N. Engl. J. Med., 1984, 311(12), 764-770.
15. O'Connor, D.T.; Deftos, L.J., Secretion of chromogranin A by peptideproducing endocrine neoplasms. N. Engl. J. Med., 1986, 314(18), 1145-1151.
16. Ceconi, C.; Ferrari, R.; Bachetti, T.; Opasich, C.; Volterrani, M.; Colombo, B.; Parrinello, G.; Corti, A., Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur. Heart J., 2002, 23(12), 967-974.
17. Corti, A.; Ferrari, R.; Ceconi, C., Chromogranin A and tumor necrosis factor alpha in heart failure. Adv. Exp. Med. Biol.), 2000, 482, 351-359.
18. Zhang, D.; Lavaux, T.; Sapin, R.; Lavigne, T.; Castelain, V.; Aunis, D.; Metz-Boutigue, M.H.; Schneider, F., Serum concentration of chromogranin A at admission: an early biomarker of severity in critically ill patients. Ann. Med., 2009, 41(1), 38-44.
19. Di Comite, G.; Previtali, P.; Rossi, C.M.; Dell'Antonio, G.; Rovere-Querini, P.; Praderio, L.; Dagna, L.; Corti, A.; Doglioni, C.; Maseri, A.; Sabbadini, M.G.; Manfredi, A.A., High blood levels of chromogranin A in giant cell arteritis identify patients refractory to corticosteroid treatment. Ann. Rheum. Dis., 2009, 68(2), 293-295.
20. Di Comite, G.; Rossi, C.M.; Marinosci, A.; Lolmede, K.; Baldissera, E.; Aiello, P.; Mueller, R.B.; Herrmann, M.; Voll, R.E.; Rovere-Querini, P.; Sabbadini, M.G.; Corti, A.; Manfredi, A.A., Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-alpha-elicited endothelial activation. J Leukoc. Biol., 2009, 85(1), 81-87.
21. O'Connor, D.T.; Mahata, S.K.; Taupenot, L.; Mahata, M.; Livsey Taylor, C.V.; Kailasam, M.T.; Ziegler, M.G.; Parmer, R.J., Chromogranin A in human disease. Adv. Exp. Med. Biol., 2000, 482, 377-388.
22. Syversen, U.; Ramstad, H.; Gamme, K.; Qvigstad, G.; Falkmer, S.; Waldum, H.L., Clinical significance of elevated serum chromogranin A levels. Scand. J. Gastroenterol., 2004, 39(10), 969-973.
23. Borch, K.; Stridsberg, M.; Burman, P.; Rehfeld, J.F., Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand. J. Gastroenterol., 1997, 32(3), 198-202.
24. Castoldi, G.; Antolini, L.; Bombardi, C.; Perego, L.; Mariani, P.; Vigano, M.R.; Torti, G.; Casati, M.; Corti, A.; Zerbini, G.; Valsecchi, M.G.; Stella, A., Oxidative stress biomarkers and chromogranin A in uremic patients: effects of dialytic treatment. Clin. Biochem., 2010, 43(18), 1387-1392.
25. Giusti, M.; Sidoti, M.; Augeri, C.; Rabitti, C.; Minuto, F., Effect of shortterm treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur. J. Endocrinol., 2004, 150(3), 299-303.
26. Sanduleanu, S.; Stridsberg, M.; Jonkers, D.; Hameeteman, W.; Biemond, I.; Lundqvist, G.; Lamers, C.; Stockbrugger, R.W., Serum gastrin and chromogranin A during medium-and long-term acid suppressive therapy: a case-control study. Aliment. Pharmacol. Ther., 1999, 13(2), 145-153.
27. Ligumsky, M.; Lysy, J.; Siguencia, G.; Friedlander, Y., Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis. J. Clin. Gastroenterol., 2001, 33(1), 32-35.
28. Waldum, H.L.; Brenna, E., Personal review: is profound acid inhibition safe? Aliment. Pharmacol. Ther., 2000, 14(1), 15-22.
29. Montero-Hadjadje, M.; Vaingankar, S.; Elias, S.; Tostivint, H.; Mahata, S.K.; Anouar, Y., Chromogranins A and B and secretogranin II: evolutionary and functional aspects. Acta Physiol (Oxf), 2008, 192(2), 309-324.
30. Eskeland, N.L.; Zhou, A.; Dinh, T.Q.; Wu, H.; Parmer, R.J.; Mains, R.E.; O'Connor, D.T., Chromogranin A processing and secretion: specific role of endogenous and exogenous prohormone convertases in the regulated secretory pathway. J. Clin. Invest., 1996, 98(1), 148-156.
31. Doblinger, A.; Becker, A.; Seidah, N.G.; Laslop, A., Proteolytic processing of chromogranin A by the prohormone convertase PC2. Regul. Pept., 2003, 111(1-3), 111-116.
32. Colombo, B.; Longhi, R.; Marinzi, C.; Magni, F.; Cattaneo, A.; Yoo, S.H.; Curnis, F.; Corti, A., Cleavage of chromogranin A N-terminal domain by plasmin provides a new mechanism for regulating cell adhesion. J. Biol. Chem., 2002, 277(48), 45911-45919.
33. Biswas, N.; Vaingankar, S.M.; Mahata, M.; Das, M.; Gayen, J.R.; Taupenot, L.; Torpey, J.W.; O'Connor, D.T.; Mahata, S.K., Proteolytic cleavage of human chromogranin a containing naturally occurring catestatin variants: differential processing at catestatin region by plasmin. Endocrinology, 2008, 149(2), 749-757.
34. Biswas, N.; Rodriguez-Flores, J.L.; Courel, M.; Gayen, J.R.; Vaingankar, S.M.; Mahata, M.; Torpey, J.W.; Taupenot, L.; O'Connor, D.T.; Mahata, S.K., Cathepsin L colocalizes with chromogranin a in chromaffin vesicles to generate active peptides. Endocrinology, 2009, 150(8), 3547-3557.
35. Metz-Boutigue, M.H.; Garcia-Sablone, P.; Hogue-Angeletti, R.; Aunis, D., Intracellular and extracellular processing of chromogranin A. Determination of cleavage sites. Eur. J. Biochem., 1993, 217(1), 247-257.
36. Wohlfarter, T.; Fischer-Colbrie, R.; Hogue-Angeletti, R.; Eiden, L.E.; Winkler, H., Processing of chromogranin A within chromaffin granules starts at C-and N-terminal cleavage sites. FEBS Lett., 1988, 231(1), 67-70.
37. Corti, A.; Gasparri, A.; Chen, F.X.; Pelagi, M.; Brandazza, A.; Sidoli, A.; Siccardi, A.G., Characterisation of circulating chromogranin A in human cancer patients. Br. J. Cancer, 1996, 73(8), 924-932.
38. Mahata, S.K.; Mahata, M.; Fung, M.M.; O'Connor, D.T., Catestatin: a multifunctional peptide from chromogranin A. Regul Pept, 2010, 162(1-3), 33-43.
39. Angelone, T.; Quintieri, A.M.; Brar, B.K.; Limchaiyawat, P.T.; Tota, B.; Mahata, S.K.; Cerra, M.C., The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism. Endocrinology, 2008, 149(10), 4780-4793.
40. Imbrogno, S.; Garofalo, F.; Cerra, M.C.; Mahata, S.K.; Tota, B., The catecholamine release-inhibitory peptide catestatin (chromogranin A344-363) modulates myocardial function in fish. J. Exp Biol., 2010, 213(Pt 21), 3636-3643.
41. Theurl, M.; Schgoer, W.; Albrecht, K.; Jeschke, J.; Egger, M.; Beer, A.G.; Vasiljevic, D.; Rong, S.; Wolf, A.M.; Bahlmann, F.H.; Patsch, J.R.; Wolf, D.; Schratzberger, P.; Mahata, S.K.; Kirchmair, R., The neuropeptide catestatin acts as a novel angiogenic cytokine via a basic fibroblast growth factor-dependent mechanism. Circ. Res., 2010, 107(11), 1326-1335.
42. Egger, M.; Beer, A.G.; Theurl, M.; Schgoer, W.; Hotter, B.; Tatarczyk, T.; Vasiljevic, D.; Frauscher, S.; Marksteiner, J.; Patsch, J.R.; Schratzberger, P.; Djanani, A.M.; Mahata, S.K.; Kirchmair, R., Monocyte migration: a novel effect and signaling pathways of catestatin. Eur. J. Pharmacol., 2008, 598(1-3), 104-111.
43. Dev, N.B.; Gayen, J.R.; O'Connor, D.T.; Mahata, S.K., Chromogranin a and the autonomic system: decomposition of heart rate variability and rescue by its catestatin fragment. Endocrinology, 2010, 151(6), 2760-2768.
44. Mahapatra, N.R.; Mahata, M.; Mahata, S.K.; O'Connor, D.T., The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle cotransmitters. J. Hypertens., 2006, 24(5), 895-904.
45. Akaddar, A.; Doderer-Lang, C.; Marzahn, M.R.; Delalande, F.; Mousli, M.; Helle, K.; Van Dorsselaer, A.; Aunis, D.; Dunn, B.M.; Metz-Boutigue, M.H.; Candolfi, E., Catestatin, an endogenous chromogranin A-derived peptide, inhibits in vitro growth of Plasmodium falciparum. Cell Mol. Life Sci., 2010, 67(6), 1005-1015.
46. Briolat, J.; Wu, S.D.; Mahata, S.K.; Gonthier, B.; Bagnard, D.; Chasserot-Golaz, S.; Helle, K.B.; Aunis, D.; Metz-Boutigue, M.H., New antimicrobial activity for the catecholamine release-inhibitory peptide from chromogranin A. Cell Mol. Life Sci., 2005, 62(3), 377-385.
47. Zhang, K.; Rao, F.; Wen, G.; Salem, R.M.; Vaingankar, S.; Mahata, M.; Mahapatra, N.R.; Lillie, E.O.; Cadman, P.E.; Friese, R.S.; Hamilton, B.A.; Hook, V.Y.; Mahata, S.K.; Taupenot, L.; O'Connor, D.T., Catecholamine storage vesicles and the metabolic syndrome: The role of the chromogranin A fragment pancreastatin. Diab. Obes. Metab., 2006, 8(6), 621-633.
48. O'Connor, D.T.; Cadman, P.E.; Smiley, C.; Salem, R.M.; Rao, F.; Smith, J.; Funk, S.D.; Mahata, S.K.; Mahata, M.; Wen, G.; Taupenot, L.; Gonzalez-Yanes, C.; Harper, K.L.; Henry, R.R.; Sanchez-Margalet, V., Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism. J. Clin. Endocrinol. Metab., 2005, 90(9), 5414-5425.
49. Sanchez-Margalet, V.; Gonzalez-Yanes, C.; Najib, S.; Santos-Alvarez, J., Reprint of: Metabolic effects and mechanism of action of the chromogranin A-derived peptide pancreastatin. Regul. Pept., 2010, 165(1), 71-77.
50. Gayen, J.R.; Saberi, M.; Schenk, S.; Biswas, N.; Vaingankar, S.M.; Cheung, W.W.; Najjar, S.M.; O'Connor, D.T.; Bandyopadhyay, G.; Mahata, S.K., A novel pathway of insulin sensitivity in chromogranin A null mice: a crucial role for pancreastatin in glucose homeostasis. J. Biol. Chem. 2009, 284(42), 28498-28509.
51. Aardal, S.; Helle, K.B., The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul. Pept., 1992, 41(1), 9-18.
52. Tota, B.; Angelone, T.; Mazza, R.; Cerra, M.C., The chromogranin Aderived vasostatins: new players in the endocrine heart. Curr. Med. Chem., 2008, 15(14), 1444-1451.
53. Imbrogno, S.; Angelone, T.; Corti, A.; Adamo, C.; Helle, K.B.; Tota, B., Influence of vasostatins, the chromogranin A-derived peptides, on the working heart of the eel (Anguilla anguilla): negative inotropy and mechanism of action. Gen. Comp. Endocrinol., 2004, 139(1), 20-28.
54. Corti, A.; Mannarino, C.; Mazza, R.; Angelone, T.; Longhi, R.; Tota, B., Chromogranin A N-terminal fragments vasostatin-1 and the synthetic CGA 7-57 peptide act as cardiostatins on the isolated working frog heart. Gen. Comp. Endocrinol., 2004, 136(2), 217-224.
55. Russell, J.; Gee, P.; Liu, S.M.; Angeletti, R.H., Inhibition of parathyroid hormone secretion by amino-terminal chromogranin peptides. Endocrinology, 1994, 135(1), 337-342.
56. Ciesielski-Treska, J.; Ulrich, G.; Taupenot, L.; Chasserot-Golaz, S.; Corti, A.; Aunis, D.; Bader, M.F., Chromogranin A induces a neurotoxic phenotype in brain microglial cells. J. Biol. Chem., 1998, 273(23), 14339-14346.
57. Nikoopour, E.; Sandrock, C.; Huszarik, K.; Krougly, O.; Lee-Chan, E.; Masteller, E.L.; Bluestone, J.A.; Singh, B., Cutting edge: vasostatin-1-derived peptide ChgA29-42 is an antigenic epitope of diabetogenic BDC2.5 T cells in nonobese diabetic mice. J. Immunol., 2011, 186(7), 3831-3835.
58. Gasparri, A.; Sidoli, A.; Sanchez, L.P.; Longhi, R.; Siccardi, A.G.; Marchisio, P.C.; Corti, A., Chromogranin A fragments modulate cell adhesion. Identification and characterization of a pro-adhesive domain. J. Biol. Chem., 1997, 272(33), 20835-20843.
59. Ratti, S.; Curnis, F.; Longhi, R.; Colombo, B.; Gasparri, A.; Magni, F.; Manera, E.; Metz-Boutigue, M.H.; Corti, A., Structure-activity relationships of chromogranin A in cell adhesion. Identification and characterization of an adhesion site for fibroblasts and smooth muscle cells. J. Biol. Chem., 2000, 275(38), 29257-29263.
60. Dondossola, E.; Gasparri, A.; Bachi, A.; Longhi, R.; Metz-Boutigue, M.H.; Tota, B.; Helle, K.B.; Curnis, F.; Corti, A., Role of vasostatin-1 C-terminal region in fibroblast cell adhesion. Cell. Mol. Life Sci., 2010, 12, 2107-2118.
61. Blois, A.; Holmsen, H.; Martino, G.; Corti, A.; Metz-Boutigue, M.H.; Helle, K.B., Interactions of chromogranin A-derived vasostatins and monolayers of phosphatidylserine, phosphatidylcholine and phosphatidylethanolamine. Regul. Pept., 2006, 134(1), 30-37.
62. Simon, J.P.; Aunis, D., Biochemistry of the chromogranin A protein family. Biochem. J., 1989, 262(1), 1-13.
63. Turquier, V.; Vaudry, H.; Jegou, S.; Anouar, Y., Frog chromogranin A messenger ribonucleic acid encodes three highly conserved peptides. Coordinate regulation of proopiomelanocortin and chromogranin A gene expression in the pars intermedia of the pituitary during background color adaptation. Endocrinology, 1999, 140, 4104-4112.
64. Bretscher, A.; Edwards, K.; Fehon, R.G., ERM proteins and merlin: integrators at the cell cortex. Nat. Rev. Mol. Cell. Biol., 2002, 3(8), 586-599.
65. Angelone, T.; Quintieri, A.M.; Goumon, Y.; Di Felice, V.; Filice, E.; Gattuso, A.; Mazza, R.; Corti, A.; Tota, B.; Metz-Boutigue, M.H.; Cerra, M.C., Cytoskeleton mediates negative inotropism and lusitropism of chromogranin A-derived peptides (human vasostatin1-78 and rat CgA(1-64)) in the rat heart. Regul. Pept., 2009, 165(1):78-78.
66. Di Felice, V.; Cappello, F.; Montalbano, A.; Ardizzone, N.; Campanella, C.; De Luca, A.; Amelio, D.; Tota, B.; Corti, A.; Zummo, G., Human recombinant vasostatin-1 may interfere with cell-extracellular matrix interactions. Ann. N.Y. Acad. Sci., 2006, 1090, 305-310.
67. Ratti, S.; Curnis, F.; Longhi, R.; Colombo, B.; Gasparri, A.; Magni, F.; Manera, E.; Metz-Boutigue, M.H.; Corti, A., Structure-activity relationships of chromogranin A in cell adhesion. Identification of an adhesion site for fibroblasts and smooth muscle cells. J. Biol. Chem., 2000, 275(38), 29257-29263.
68. Komarova, Y.; Malik, A.B., Regulation of endothelial permeability via paracellular and transcellular transport pathways. Annu. Rev. Physiol., 2010, 72, 463-493.
69. Lum, H.; Malik, A.B., Regulation of vascular endothelial barrier function. Am. J. Physiol., 1994, 267(3 Pt 1), L223-241.
70. Cardoso, F.L.; Brites, D.; Brito, M.A., Looking at the blood-brain barrier: molecular anatomy and possible investigation approaches. Brain Res. Rev., 2010, 64(2), 328-363.
71. Sandoval, K.E.; Witt, K.A., Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol. Dis., 2008, 32(2), 200-219.
72. Takakura, Y.; Mahato, R.I.; Hashida, M., Extravasation of macromolecules. Adv. Drug Deliv. Rev., 1998, 34(1), 93-108.
73. Aird, W.C., Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ. Res., 2007, 100(2), 158-173.
74. Hu, G.; Place, A.T.; Minshall, R.D., Regulation of endothelial permeability by Src kinase signaling: vascular leakage versus transcellular transport of drugs and macromolecules. Chem. Biol. Interact., 2008, 171(2), 177-189.
75. Mehta, D.; Malik, A.B., Signaling mechanisms regulating endothelial permeability. Physiol. Rev., 2006, 86(1), 279-367.
76. Wallez, Y.; Huber, P., Endothelial adherens and tight junctions in vascular homeostasis, inflammation and angiogenesis. Biochim. Biophys. Acta, 2008, 1778(3), 794-809.
77. Kumar, P.; Shen, Q.; Pivetti, C.D.; Lee, E.S.; Wu, M.H.; Yuan, S.Y., Molecular mechanisms of endothelial hyperpermeability: implications in inflammation. Expert. Rev. Mol. Med., 2009, 11, e19.
78. Lum, H.; Malik, A.B., Regulation of vascular endothelial barrier function. Am. J. Physiol., 1994, 267(3 Pt 1), L223-241.
79. Ferrero, E.; Ferrero, M.E.; Pardi, R.; Zocchi, M.R., The platelet endothelial cell adhesion molecule-1 (PECAM1) contributes to endothelial barrier function. FEBS Lett., 1995, 374(3), 323-326.
80. Bazzoni, G.; Martinez Estrada, O.; Dejana, E., Molecular structure and functional role of vascular tight junctions. Trends Cardiovasc. Med., 1999, 9(6), 147-152.
81. Runkle, E.A.; Antonetti, D.A., The blood-retinal barrier: structure and functional significance. Meth. Mol. Biol., 2011, 686, 133-148.
82. Nag, S.; Kapadia, A.; Stewart, D.J., Review: molecular pathogenesis of blood-brain barrier breakdown in acute brain injury. Neuropathol. Appl. Neurobiol., 2011, 37(1), 3-23.
83. Vestweber, D.; Broermann, A.; Schulte, D., Control of endothelial barrier function by regulating vascular endothelial-cadherin. Curr. Opin. Hematol., 2010, 17(3), 230-236.
84. Xiao, K.; Garner, J.; Buckley, K.M.; Vincent, P.A.; Chiasson, C.M.; Dejana, E.; Faundez, V.; Kowalczyk, A.P., p120-Catenin regulates clathrindependent endocytosis of VE-cadherin. Mol. Biol. Cell, 2005, 16(11), 5141-5151.
85. Dejana, E., Endothelial cell-cell junctions: happy together. Nat. Rev. Mol. Cell. Biol., 2004, 5(4), 261-270.
86. Privratsky, J.R.; Paddock, C.M.; Florey, O.; Newman, D.K.; Muller, W.A.; Newman, P.J., Relative contribution of PECAM-1 adhesion and signaling to the maintenance of vascular integrity. J. Cell Sci., 2011, 124, (Pt 9), 1477-1485.
87. Prasain, N.; Stevens, T., The actin cytoskeleton in endothelial cell phenotypes. Microvasc. Res., 2009, 77(1), 53-63.
88. Bogatcheva, N.V.; Verin, A.D., The role of cytoskeleton in the regulation of vascular endothelial barrier function. Microvasc. Res., 2008, 76(3), 202-207.
89. Vandenbroucke, E.; Mehta, D.; Minshall, R.; Malik, A.B., Regulation of endothelial junctional permeability. Ann. N. Y. Acad. Sci., 2008, 1123, 134-145.
90. Ferrero, E.; Zocchi, M.R.; Magni, E.; Panzeri, M.C.; Curnis, F.; Rugarli, C.; Ferrero, M.E.; Corti, A., Roles of tumor necrosis factor p55 and p75 receptors in TNF-alpha-induced vascular permeability. Am. J. Physiol. Cell Physiol., 2001, 281(4), C1173-1179.
91. Ferrero, E.; Villa, A.; Ferrero, M.E.; Toninelli, E.; Bender, J.R.; Pardi, R.; Zocchi, M.R., Tumor necrosis factor alpha-induced vascular leakage involves PECAM1 phosphorylation. Cancer Res., 1996, 56(14), 3211-3215.
92. Shasby, D.M.; Shasby, S.S.; Sullivan, J.M.; Peach, M.J., Role of endothelial cell cytoskeleton in control of endothelial permeability. Circ. Res., 1982, 51(5), 657-661.
93. Phillips, P.G.; Lum, H.; Malik, A.B.; Tsan, M.F., Phallacidin prevents thrombin-induced increases in endothelial permeability to albumin. Am. J. Physiol., 1989, 257(3 Pt 1), C562-567.
94. Wojciak-Stothard, B.; Ridley, A.J., Rho GTPases and the regulation of endothelial permeability. Vascul. Pharmacol., 2002, 39(4-5), 187-199.
95. Vouret-Craviari, V.; Boquet, P.; Pouyssegur, J.; Van Obberghen-Schilling, E., Regulation of the actin cytoskeleton by thrombin in human endothelial cells: role of Rho proteins in endothelial barrier function. Mol. Biol. Cell, 1998, 9(9), 2639-2653.
96. Lampugnani, M.G.; Zanetti, A.; Breviario, F.; Balconi, G.; Orsenigo, F.; Corada, M.; Spagnuolo, R.; Betson, M.; Braga, V.; Dejana, E., VE-cadherin regulates endothelial actin activating Rac and increasing membrane association of Tiam. Mol. Biol. Cell, 2002, 13(4), 1175-1189.
97. Ferrero, E.; Scabini, S.; Magni, E.; Foglieni, C.; Belloni, D.; Colombo, B.; Curnis, F.; Villa, A.; Ferrero, M.E.; Corti, A., Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage. FASEB J., 2004, 20, 20.
98. Belloni, D.; Scabini, S.; Foglieni, C.; Veschini, L.; Giazzon, A.; Colombo, B.; Fulgenzi, A.; Helle, K.B.; Ferrero, M.E.; Corti, A.; Ferrero, E., The vasostatin-I fragment of chromogranin A inhibits VEGF-induced endothelial cell proliferation and migration. FASEB J., 2007, 21, 3052-3062.
99. Veschini, L.; Crippa, L.; Dondossola, E.; Doglioni, C.; Corti, A.; Ferrero, E., The vasostatin-1 fragment of chromogranin A preserves a quiescent phenotype in hypoxia-driven endothelial cells and regulates tumor neovascularization. FASEB J, 2011, 25(11):3906-14.
100. Blois, A.; Srebro, B.; Mandalà, M.; Corti, A.; Helle, K.B.; Serck-Hanssen, G., The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells. Regul. Pept., 2006, 135, 78-84.
101. Waltenberger, J.; Claesson-Welsh, L.; Siegbahn, A.; Shibuya, M.; Heldin, C.H., Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem., 1994, 269(43), 26988-26995.
102. Mandalà, M.; Stridsberg, M.; Helle, K.B.; Serck-Hanssen, G., Endothelial handling of chromogranin A. Adv. Exp. Med. Biol., 2000, 482, 167-178.
103. Ramella, R.; Boero, O.; Alloatti, G.; Angelone, T.; Levi, R.; Gallo, M.P., Vasostatin 1 activates eNOS in endothelial cells through a proteoglycandependent mechanism. J. Cell. Biochem., 2010, 110(1), 70-79.
104. Maget-Dana, R.; Metz-Boutigue, M.H.; Helle, K.B., The N-terminal domain of chromogranin A (CgA1-40) interacts with monolayers of membrane lipids of fungal and mammalian compositions. Ann. N. Y. Acad. Sci., 2002, 971, 352-354.
105. Zhang, D.; Shooshtarizadeh, P.; Laventie, B.J.; Colin, D.A.; Chich, J.F.; Vidic, J.; de Barry, J.; Chasserot-Golaz, S.; Delalande, F.; Van Dorsselaer, A.; Schneider, F.; Helle, K.; Aunis, D.; Prevost, G.; Metz-Boutigue, M.H., Two chromogranin a-derived peptides induce calcium entry in human neutrophils by calmodulin-regulated calcium independent phospholipase A2. PLoS One, 2009, 4(2), e4501.
106. Gregorc, V.; Spreafico, A.; Floriani, I.; Colombo, B.; Ludovini, V.; Pistola, L.; Bellezza, G.; Vigano, M.G.; Villa, E.; Corti, A., Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer. Cancer, 2007, 110(4), 845-853.
107. Chen, Y.; Mahata, M.; Rao, F.; Khandrika, S.; Courel, M.; Fung, M.M.; Zhang, K.; Stridsberg, M.; Ziegler, M.G.; Hamilton, B.A.; Lipkowitz, M.S.; Taupenot, L.; Nievergelt, C.; Mahata, S.K.; O'Connor, D.T., Chromogranin A regulates renal function by triggering Weibel-Palade body exocytosis. J. Am. Soc. Nephrol., 2009, 20(7), 1623-1632.
108. Sidhu, R.; Drew, K.; McAlindon, M.E.; Lobo, A.J.; Sanders, D.S., Elevated serum chromogranin A in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD): a shared model for pathogenesis? Inflamm. Bowel Dis., 2010, 16(3), 361.
109. Jansson, A.M.; Rosjo, H.; Omland, T.; Karlsson, T.; Hartford, M.; Flyvbjerg, A.; Caidahl, K., Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur. Heart J., 2009, 30(1), 25-32.
110. Capellino, S.; Lowin, T.; Angele, P.; Falk, W.; Grifka, J.; Straub, R.H., Increased chromogranin A levels indicate sympathetic hyperactivity in patients with rheumatoid arthritis and systemic lupus erythematosus. J. Rheumatol., 2008, 35(1), 91-99.
111. Corti, A.; Ferrari, R.; Ceconi, C., Chromogranin A and tumor necrosis factoralpha (TNF) in chronic heart failure. Adv. Exp. Med. Biol., 2000, 482, 351-359.
112. Yu, M.; Wang, Z.; Fang, Y.; Xiao, M.D.; Yuan, Z.X.; Lu, C.B.; Lin, L.; Yang, D.C., Overexpression of Vasostatin-1 Protects Hypoxia/Reoxygenation Injuries in Cardiomyocytes Independent of Endothelial Cells. Cardiovasc. Ther., 2011, doi: 10.1111/j.1755-5922.2011.00270
113. Roatta, S.; Passatore, M.; Novello, M.; Colombo, B.; Dondossola, E.; Mohammed, M.; Losano, G.; Corti, A.; Helle, K.B., The chromogranin Aderived N-terminal peptide vasostatin-I: In vivo effects on cardiovascular variables in the rabbit. Regul. Pept., 2011, 168(1-3), 10-20.
114. Rao, F.; Wen, G.; Gayen, J.R.; Das, M.; Vaingankar, S.M.; Rana, B.K.; Mahata, M.; Kennedy, B.P.; Salem, R.M.; Stridsberg, M.; Abel, K.; Smith, D.W.; Eskin, E.; Schork, N.J.; Hamilton, B.A.; Ziegler, M.G.; Mahata, S.K.; O'Connor, D.T., Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation, 2007, 115(17), 2271-2281.
115. di Comite, G.; Marinosci, A.; Di Matteo, P.; Manfredi, A.; Rovere-Querini, P.; Baldissera, E.; Aiello, P.; Corti, A.; Sabbadini, M.G., Neuroendocrine modulation induced by selective blockade of TNF-alpha in rheumatoid arthritis. Ann. N. Y. Acad. Sci., 2006, 1069, 428-437.
116. Zhang, D.; Lavaux, T.; Voegeli, A.C.; Lavigne, T.; Castelain, V.; Meyer, N.; Sapin, R.; Aunis, D.; Metz-Boutigue, M.H.; Schneider, F., Prognostic value of chromogranin A at admission in critically ill patients: a cohort study in a medical intensive care unit. Clin. Chem., 2008, 54(9), 1497-1503.
117. Minchinton, A.I.; Tannock, I.F., Drug penetration in solid tumours. Nat. Rev. Cancer, 2006, 6(8), 583-592.
118. Tredan, O.; Galmarini, C.M.; Patel, K.; Tannock, I.F., Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst., 2007, 99(19), 1441-1454.
119. Colombo, B.; Curnis, F.; Foglieni, C.; Monno, A.; Arrigoni, G.; Corti, A., Chromogranin a expression in neoplastic cells affects tumor growth and morphogenesis in mouse models. Cancer Res., 2002, 62(3), 941-946.
120. Dondossola, E.; Gasparri, A.M.; Colombo, B.; Sacchi, A.; Curnis, F.; Corti, A., Chromogranin A Restricts Drug Penetration and Limits the Ability of NGR-TNF to Enhance Chemotherapeutic Efficacy. Cancer Res., 2011, 71(17), 5881-5890.
121. Fischer-Colbrie, R.; Kirchmair, R.; Kahler, C.M.; Wiedermann, C.J.; Saria, A., Secretoneurin: a new player in angiogenesis and chemotaxis linking nerves, blood vessels and the immune system. Curr. Protein Pept. Sci., 2005, 6(4), 373-385.
122. Yan, S.; Wang, X.; Chai, H.; Wang, H.; Yao, Q.; Chen, C., Secretoneurin increases monolayer permeability in human coronary artery endothelial cells. Surgery, 2006, 140(2), 243-251.
123. Corti, A.; Pastorino, F.; Curnis, F.; Arap, W.; Ponzoni, M.; Pasqualini, R., Targeted drug delivery and penetration into solid tumors. Med. Res. Rev., 2011, doi: 10.1002/med.20238.
124. Curnis, F.; Sacchi, A.; Borgna, L.; Magni, F.; Gasparri, A.; Corti, A., Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol., 2000, 18(11), 1185-1190.
125. Curnis, F.; Arrigoni, G.; Sacchi, A.; Fischetti, L.; Arap, W.; Pasqualini, R.; Corti, A., Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res., 2002, 62(3), 867-874.
126. Arap, W.; Pasqualini, R.; Ruoslahti, E., Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 1998, 279(5349), 377-380.
127. Pasqualini, R.; Koivunen, E.; Kain, R.; Lahdenranta, J.; Sakamoto, M.; Stryhn, A.; Ashmun, R.A.; Shapiro, L.H.; Arap, W.; Ruoslahti, E., Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res., 2000, 60(3), 722-727.
128. Curnis, F.; Sacchi, A.; Corti, A., Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J. Clin. Invest., 2002, 110(4), 475-482.
129. Sacchi, A.; Gasparri, A.; Gallo-Stampino, C.; Toma, S.; Curnis, F.; Corti, A., Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha. Clin. Cancer Res., 2006, 12(1), 175-182.
130. Vaingankar, S.M.; Li, Y.; Biswas, N.; Gayen, J.; Choksi, S.; Rao, F.; Ziegler, M.G.; Mahata, S.K.; O'Connor, D.T., Effects of chromogranin A deficiency and excess in vivo: biphasic blood pressure and catecholamine responses. J. Hypertens., 2010, 28(4), 817-825.
131. Ross, R.W.; Beer, T.M.; Jacobus, S.; Bubley, G.J.; Taplin, M.E.; Ryan, C.W.; Huang, J.; Oh, W.K., A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer, 2008, 112(3), 521-526.
132. Johnson, P.W.; Joel, S.P.; Love, S.; Butcher, M.; Pandian, M.R.; Squires, L.; Wrigley, P.F.; Slevin, M.L., Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br. J. Cancer, 1993, 67(4), 760-766.
133. Cabrespine, A.; Guy, L.; Gachon, F.; Cure, H.; Chollet, P.; Bay, J.O., Circulating chromogranin a and hormone refractory prostate cancer chemotherapy. J. Urol., 2006, 175(4), 1347-1352.